Literature DB >> 24298481

Role of common investigations in aetiological evaluation of exudative pleural effusions.

Arnab Maji1, Malay Kumar Maikap, Debraj Jash, Kaushik Saha, Abhijit Kundu, Debabrata Saha, Sourindranath Banerjee, Anupam Patra.   

Abstract

BACKGROUND: Pleural effusion is a common problem encountered in daily practice. To Establish aetiology of exudative effusions is a diagnostic challenge to general practitioners and even to pulmonologists especially in resource poor government hospitals with lack of investigations like thoracoscopy. Some recent studies had shown that around 2% of patients remained undiagnosed even after these investigations. AIMS AND
OBJECTIVE: To evaluate the role of the commonly available investigations such as pleural fluid study, blind pleural biopsy, sputum examination, CT scan thorax, bronchoscopy in the aetiological evaluation of exudative effusions and to ascertain the proportion of cases which remain undiagnosed after all the above investigations.
MATERIAL AND METHODS: This was a prospective single-centred cross-sectional study carried out at the NRS Medical College, Kolkata, India from February 2008 to February 2013 which included 568 patients of exudative pleural effusions. We performed commonly available procedures like pleural fluid study, blind pleural biopsy, sputum examination, CT scan thorax, bronchoscopic procedures to the diagnosis.
RESULTS: Total number of patients studied were 568. Tuberculosis was the most common cause (54.57%) followed by malignancy (28.17%), empyema (10.56%), parapneumonic effusion (5.28%) and others. Carcinoma of the lung was the commonest cause of malignant effusions and bronchoscopic biopsy was given the highest yield of histological diagnosis (84.6%) followed by CT guided FNAC (77.6%) and pleural fluid cytology (55%). Highest yield to diagnose tubercular effusion was found in lymph node FNAC (81.5%) followed by pleural biopsy (62%). Sputum smear for AFB was positive in only 27.4% cases. Bleeding followed by pneumothorax were the most common complications. Complications are very less (1.3% and 0.9% respectively). 2 patients (0.34%) remained undiagnosed even after these all above said investigations.
CONCLUSION: Above mentioned commonly available investigations can ascertain diagnosis in most of the cases in the aetiological evaluation of exudative effusions and they are relatively safe procedures.

Entities:  

Keywords:  Bronchoscopy; Exudative; Investigations; Malignancy; Pleural biopsy; Pleural effusion; Tuberculosis

Year:  2013        PMID: 24298481      PMCID: PMC3843477          DOI: 10.7860/JCDR/2013/6738.3476

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  21 in total

1.  Diagnostic value of adenosine deaminase in tuberculous pleural effusion: a meta-analysis.

Authors:  Masashi Goto; Yoshinori Noguchi; Hiroshi Koyama; Kenji Hira; Takuro Shimbo; Tsuguya Fukui
Journal:  Ann Clin Biochem       Date:  2003-07       Impact factor: 2.057

2.  Pleural effusions: role of commonly available investigations.

Authors:  S H How; S P Chin; A R Zal; C K Liam
Journal:  Singapore Med J       Date:  2006-07       Impact factor: 1.858

3.  Diagnostic value of simultaneous determination of pleural adenosine deaminase and pleural lysozyme/serum lysozyme ratio in pleural effusions.

Authors:  J Fontan Bueso; H Verea Hernando; J P Garcia-Buela; L Dominguez Juncal; M T Martin Egaña; M C Montero Martinez
Journal:  Chest       Date:  1988-02       Impact factor: 9.410

4.  Hemothorax and hyperkalemia after pleural biopsy in a 43-year-old woman on hemodialysis.

Authors:  J Ali; W R Summer
Journal:  Chest       Date:  1994-10       Impact factor: 9.410

5.  [The usefulness of pleural biopsy in benign or malignant pleurisy].

Authors:  Y Inoue; N Miura; T Watanabe; K Watanabe; T Tsutsumi; Y Doutsu; S Kohno; T Kanda; M Hirota; K Hara
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1991-03

6.  Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study.

Authors:  J S Ferrer; X G Muñoz; R M Orriols; R W Light; F B Morell
Journal:  Chest       Date:  1996-06       Impact factor: 9.410

7.  Utility of tumour markers in the diagnosis of neoplastic pleural effusion.

Authors:  M E San Jose; D Alvarez; L Valdes; A Sarandeses; J M Valle; P Penela
Journal:  Clin Chim Acta       Date:  1997-09-30       Impact factor: 3.786

8.  Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases.

Authors:  U B Prakash; H M Reiman
Journal:  Mayo Clin Proc       Date:  1985-03       Impact factor: 7.616

9.  Pleural effusion: laboratory tests in 300 cases.

Authors:  A Hirsch; P Ruffie; M Nebut; J Bignon; J Chrétien
Journal:  Thorax       Date:  1979-02       Impact factor: 9.139

10.  Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma.

Authors:  L Valdés; E San José; D Alvarez; A Sarandeses; A Pose; B Chomón; J M Alvarez-Dobaño; M Salgueiro; J R Rodríguez Suárez
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

View more
  3 in total

1.  Pleural fluid adenosine deaminase/serum C-reactive protein ratio for the differentiation of tuberculous and parapneumonic effusions with neutrophilic predominance and high adenosine deaminase levels.

Authors:  Jaehee Lee; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Chang Ho Kim
Journal:  Infection       Date:  2016-08-03       Impact factor: 3.553

2.  Radiologic and laboratory differences in patients with tuberculous and parapneumonic pleural effusions showing non-lymphocytic predominance and high adenosine deaminase levels.

Authors:  J Lee; S Y Lee; J K Lim; S S Yoo; S Y Lee; S I Cha; J Y Park; C H Kim
Journal:  Infection       Date:  2014-11-11       Impact factor: 3.553

3.  Different characteristics of tuberculous pleural effusion according to pleural fluid cellular predominance and loculation.

Authors:  Jaehee Lee; Jae Kwang Lim; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Chang Ho Kim
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.